Since being established in November 2014, OIRM has made a serious impact on a budget of approximately $5M per year and a lean (but not mean!) staff of six, supported by five part-time advisors. Highlights include:

  • Partnered to generate leveraged funding of $42.5M (almost 7-fold!) in 2016-2017
  • Invested $7.5M into translational Disease Teams as they move into clinical trials and over $1.6M in discovery-based research to feed the pipeline
  • Supported the development of the lead technology that led to the formation of BlueRock Therapeutics
  • Helped Increase the number of Ontario cell therapy trials from five to 13
  • Provided $7M in funding to support CCRM’s business development and technology platforms leading to four spin-off companies and three company relocations to Ontario since 2014
  • Fostered a robust network across the province, increasing it from 145 programs in 2014 to over 250 programs in 2017, representing a network of over 2,000 scientists, clinicians and HQP
  • Catalyzed 41 partnerships with private sector firms, universities, hospitals and not-for-profits

Learn more about our accomplishments: